Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GPR88 | Q9GZN0 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | MAN2A1 | Q16706 | 1/20 | 0.38 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686195 | 0.86 | CHRNB2 (0.48) | ALDH1A1 | |
| SCHEMBL19686198 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1ROCK2ROCK1 | |
| SCHEMBL21325176 | 0.81 | TACR1 (0.41) | ALDH1A1MAPTHPGDGPR88MAN2A1 | |
| SCHEMBL19686208 | 0.78 | ALDH1A1 (0.40) | ALDH1A1ROCK2MAPK1EGFR | |
| SCHEMBL21325309 | 0.77 | SCN9A (0.53) | KMT2AMEN1MAPK1 | |
| SCHEMBL19685918 | 0.77 | SCN8A (0.40) | ALDH1A1ROCK1HPGDMAN2A1MAN1B1 | |
| SCHEMBL21325172 | 0.77 | SCN4A (0.52) | ALDH1A1KMT2AHTT | |
| SCHEMBL19685920 | 0.74 | TAS1R3 (0.39) | ALDH1A1MAPTHPGDMAN2A1MAN1B1 | |
| SCHEMBL31407140 | 0.74 | MAOA (0.44) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL19668715 | 0.74 | HTR1B (0.47) | ALDH1A1KMT2AMAPTHPGDMAN2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2017210371-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | SCN1B, CACNA1E, SCN2B | ALDH1A1 1414/4885KMT2A 4124/4885MEN1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.